Literature DB >> 19476401

Polypharmacy among disabled Taiwanese elderly: a longitudinal observational study.

Ding-Cheng Derrick Chan1, Yi-Ting Hao, Shwu-Chong Wu.   

Abstract

BACKGROUND AND
OBJECTIVE: It is not known whether the correlates of polypharmacy among disabled elderly are similar to those for older adults in general. Furthermore, data on polypharmacy in the Taiwanese population are limited. Therefore, this study was conducted to determine the prevalence and correlates of polypharmacy among disabled Taiwanese elderly (aged >or=65 years).
METHODS: This was a longitudinal observational study conducted on information obtained between July 2001 and June 2002. Study participants consisted of nationally representative samples of 11,788 disabled Taiwanese elderly from the ANLTCNT (Assessment of National Long-Term Care Need in Taiwan) study. Polypharmacy and major polypharmacy were defined as prescription of >or=5 and >or=10 medications, respectively, on the day of maximum numbers of prescriptions of the study year. Subject characteristics were derived from the ANLTCNT study survey data. Healthcare-related characteristics, including medication prescriptions, were obtained from the National Health Insurance (NHI) claims data. Multivariate logistic regression was performed for statistical analysis.
RESULTS: One-fifth (21.5%) of the sample were aged >or=85 years, and 58% were female. The prevalence of polypharmacy and major polypharmacy among disabled Taiwanese elderly was 81% and 38%, respectively. Nearly one-third (32.5%) of disabled Taiwanese elderly were exposed to polypharmacy for >or=181 days in 1 year. Compared with those with a low tendency for visiting multiple providers, those with intermediate tendency (odds ratio [OR] 3.61; 95% CI 3.11, 4.18) and those with high tendency (OR 10.24; 95% CI 8.56, 12.24) were more likely to be exposed to polypharmacy. Other significant correlates of polypharmacy in the multivariate logistic regression model included age <85 years, living in urban areas, higher number of chronic conditions, poorer physical functioning, preference for visiting independent clinics and not being institutionalized.
CONCLUSION: The prevalence of polypharmacy was extremely high among disabled Taiwanese elderly. Visiting multiple healthcare providers was one of the strongest correlates. Policies that encourage the disabled elderly to establish primary care relationships and that promote geriatric care models may decrease the prevalence of polypharmacy and associated adverse outcomes in this group.

Entities:  

Mesh:

Year:  2009        PMID: 19476401     DOI: 10.2165/00002512-200926040-00005

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  33 in total

1.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION.

Authors:  S KATZ; A B FORD; R W MOSKOWITZ; B A JACKSON; M W JAFFE
Journal:  JAMA       Date:  1963-09-21       Impact factor: 56.272

Review 2.  Health outcomes and polypharmacy in elderly individuals: an integrated literature review.

Authors:  Susan C Frazier
Journal:  J Gerontol Nurs       Date:  2005-09       Impact factor: 1.254

3.  Polypharmacy among older men in South Wales.

Authors:  H F Thomas; P M Sweetnam; B Janchawee; D K Luscombe
Journal:  Eur J Clin Pharmacol       Date:  1999-07       Impact factor: 2.953

4.  Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents.

Authors:  Julia K Nguyen; Michelle M Fouts; Sharon E Kotabe; Eunice Lo
Journal:  Am J Geriatr Pharmacother       Date:  2006-03

5.  Complexity of medication use in the Veterans Affairs healthcare system: Part I: Outpatient use in relation to age and number of prescribers.

Authors:  Sheldon H Preskorn; Beryl Silkey; Rozina Shah; Melissa Neff; Teresa L Jones; Joe Choi; Amanda L Golbeck
Journal:  J Psychiatr Pract       Date:  2005-01       Impact factor: 1.325

6.  A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients.

Authors:  E Pfeiffer
Journal:  J Am Geriatr Soc       Date:  1975-10       Impact factor: 5.562

7.  Multiuse of medicines in Finland.

Authors:  T Klaukka; M Mäkelä; J Sipilä; J Martikainen
Journal:  Med Care       Date:  1993-05       Impact factor: 2.983

8.  The consumption of drugs by 75-year-old individuals living in their own homes.

Authors:  I Barat; F Andreasen; E M Damsgaard
Journal:  Eur J Clin Pharmacol       Date:  2000-09       Impact factor: 2.953

9.  The development of polypharmacy. A longitudinal study.

Authors:  L Veehof; R Stewart; F Haaijer-Ruskamp; B M Jong
Journal:  Fam Pract       Date:  2000-06       Impact factor: 2.267

10.  Use of medications by persons 65 and over: data from the established populations for epidemiologic studies of the elderly.

Authors:  E A Chrischilles; D J Foley; R B Wallace; J H Lemke; T P Semla; J T Hanlon; R J Glynn; A M Ostfeld; J M Guralnik
Journal:  J Gerontol       Date:  1992-09
View more
  16 in total

1.  Optimizing elderly pharmacotherapy: polypharmacy vs. undertreatment. Are these two concepts related?

Authors:  Encarnación Blanco-Reina; Gabriel Ariza-Zafra; Ricardo Ocaña-Riola; Matilde León-Ortíz; Inmaculada Bellido-Estévez
Journal:  Eur J Clin Pharmacol       Date:  2014-11-09       Impact factor: 2.953

2.  The Association Between Polypharmacy and Physical Function in Older Adults: a Systematic Review.

Authors:  Andreas Katsimpris; Jacob Linseisen; Christa Meisinger; Konstantinos Volaklis
Journal:  J Gen Intern Med       Date:  2019-06-25       Impact factor: 5.128

3.  Prevalence and risk of polypharmacy among the elderly in an outpatient setting: a retrospective cohort study in the Emilia-Romagna region, Italy.

Authors:  S Lane Slabaugh; Vittorio Maio; Megan Templin; Safiya Abouzaid
Journal:  Drugs Aging       Date:  2010-12-01       Impact factor: 3.923

4.  Degree of Polypharmacy and Cognitive Function in Older Women with HIV.

Authors:  Leah H Rubin; Ava G Neijna; Qiuhu Shi; Donald R Hoover; Bani Tamraz; Kathryn Anastos; Andrew Edmonds; Margaret A Fischl; Deborah Gustafson; Pauline M Maki; Daniel Merenstein; Anandi N Sheth; Gayle Springer; David Vance; Kathleen M Weber; Anjali Sharma
Journal:  AIDS Res Hum Retroviruses       Date:  2022-04-26       Impact factor: 1.723

5.  Frequency and Predictors of Polypharmacy in US Medicare Patients: A Cross-Sectional Analysis at the Patient and Physician Levels.

Authors:  Michael I Ellenbogen; Peiqi Wang; Heidi N Overton; Christine Fahim; Angela Park; William E Bruhn; Jennifer L Carnahan; Amy M Linsky; Seki A Balogun; Martin A Makary
Journal:  Drugs Aging       Date:  2020-01       Impact factor: 3.923

6.  Characteristics of ambulatory care visits to family medicine specialists in Taiwan: a nationwide analysis.

Authors:  An-Min Lynn; Tzu-Chien Shih; Cheng-Hao Hung; Ming-Hwai Lin; Shinn-Jang Hwang; Tzeng-Ji Chen
Journal:  PeerJ       Date:  2015-08-06       Impact factor: 2.984

7.  Patients Aged 80 Years or Older are Encountered More Potentially Inappropriate Medication Use.

Authors:  Li Mo; Ding Ding; Shi-Yun Pu; Qin-Hui Liu; Hong Li; Bi-Rong Dong; Xiao-Yan Yang; Jin-Han He
Journal:  Chin Med J (Engl)       Date:  2016-01-05       Impact factor: 2.628

8.  Prevalence, risk factors and health outcomes associated with polypharmacy among urban community-dwelling older adults in multi-ethnic Malaysia.

Authors:  Li Min Lim; Megan McStea; Wen Wei Chung; Nuruljannah Nor Azmi; Siti Azdiah Abdul Aziz; Syireen Alwi; Adeeba Kamarulzaman; Shahrul Bahyah Kamaruzzaman; Siew Siang Chua; Reena Rajasuriar
Journal:  PLoS One       Date:  2017-03-08       Impact factor: 3.240

9.  Is Excessive Polypharmacy a Transient or Persistent Phenomenon? A Nationwide Cohort Study in Taiwan.

Authors:  Yi-Jen Wang; Shu-Chiung Chiang; Pei-Chen Lee; Yu-Chun Chen; Li-Fang Chou; Yueh-Ching Chou; Tzeng-Ji Chen
Journal:  Front Pharmacol       Date:  2018-02-20       Impact factor: 5.810

10.  Prevalence and predictors of polypharmacy among Korean elderly.

Authors:  Hong-Ah Kim; Ju-Young Shin; Mi-Hee Kim; Byung-Joo Park
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.